Xtant Medical Reports Significant Financial Progress
Total revenue for the recent quarter reached $33.3 million, marking a 19% increase year-over-year, demonstrating the company's robust growth.
Key Financial Highlights for Q3 2025
Revenue Growth
Revenue growth can be attributed primarily to increases in licensing revenue. The company achieved a gross margin of 66.1%, a substantial rise from 58.4% in the previous year.
Net Income and Cash Flow
Xtant Medical delivered a positive net income of $1.3 million, a turnaround from a net loss of $5.0 million in the prior year. This quarter also saw the company generating $4.6 million from operating cash flow.
Future Revenue Guidance
The company reiterates its Full-Year 2025 revenue guidance, projecting revenue between $131 million and $135 million, which corresponds to a growth range of 11% to 15% compared to FY24.
Recent Business Developments
Among other notable recent developments, Xtant Medical announced plans to sell certain non-core assets, including their Coflex® and CoFix® lines, to Companion Spine, with the closing expected by year-end.
Strategic Outlook
Sean Browne, President and CEO, emphasized the goal of sustained free cash flow amidst a backdrop of expanding biologics product revenue growth. He expressed confidence in the company's trajectory due to new product launches.
Third Quarter Financial Results Summary
- Revenue of $33.3 million, reflecting a significant 19% year-over-year increase.
- Gross margin achieved at 66.1%, indicative of improved sales strategies.
- Net income stood at $1.3 million, showcasing a healthy transition from previous losses.
- Adjusted EBITDA totaled $4.5 million, contrasting previous losses.
- Operational cash flow generated was $4.6 million.
Conference Call and Future Events
The company has scheduled a conference call for interested stakeholders to discuss these results and future endeavors in more detail.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. specializes in developing innovative surgical solutions for spinal and orthopedic conditions, aligning its objectives with patient care and ethical responsibility.
Frequently Asked Questions
What was Xtant Medical's revenue for Q3 2025?
In Q3 2025, Xtant Medical reported a revenue of $33.3 million.
How did the net income change compared to the previous year?
The company achieved a net income of $1.3 million, a significant improvement from a net loss of $5.0 million in the previous year.
What is the guidance for FY2025 revenue?
Xtant Medical is forecasting full-year revenue of between $131 million and $135 million.
What strategic plans does Xtant Medical have for the future?
Xtant Medical plans to close the sale of certain non-core assets and focus on its biologics business, which is expected to propel growth.
Who is the CEO of Xtant Medical?
Sean Browne serves as the President and CEO of Xtant Medical Holdings, Inc.
